Patent: 9,421,129
✉ Email this page to a colleague
Summary for Patent: 9,421,129
Title: | Intraocular delivery devices and methods therefor |
Abstract: | Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall. The resistance component may be disposed on a removable injector attachment or on a portion of the injection device housing. Other devices may include a filter for the removal of air, infectious agents, and/or other particulate matter from the composition before the composition is injected into the eye. Related methods and systems comprising the devices are also described. |
Inventor(s): | Lerner; Leonid E. (Newport Beach, CA) |
Assignee: | OcuJect, LLC (Newport Beach, CA) |
Application Number: | 13/841,144 |
Patent Claims: | see list of patent claims |
Details for Patent 9,421,129
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Subscribe | 2032-04-02 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | June 30, 2006 | ⤷ Subscribe | 2032-04-02 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | August 10, 2012 | ⤷ Subscribe | 2032-04-02 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | October 13, 2016 | ⤷ Subscribe | 2032-04-02 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | March 20, 2018 | ⤷ Subscribe | 2032-04-02 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |